Please ensure Javascript is enabled for purposes of website accessibility

United Therapeutics reaches deal for Remodulin system

United Therapeutics Corp., a Silver Spring-based biotechnology company, announced it has signed an agreement with DEKA Research & Development Corp. for the development of a subcutaneous delivery of United Therapeutics’ Remodulin injection via a pre-filled, semi-disposable pump system. Remodulin is a treatment for pulmonary arterial hypertension symptoms associated with exercise. The delivery system could be ready by 2016, United Therapeutics said. No financial terms of the deal were announced.